Gariane Gunter, MD
Psychiatry · Columbia, SCNPI 1386774974
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,550 of the $45,827 with a category attached, or 86.3%. AbbVie accounts for 94.1% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $34,623, more than ten times the $125 reported in 2019. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $139.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Neurocrine Biosciences, Inc.$960
- Teva Pharmaceuticals USA, Inc.$606
- Otsuka America Pharmaceutical, Inc.$250
- Johnson & Johnson$234
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$206
- plus $447 from 10 others
What the payments were for
- Speaking & faculty fees$39,55086%
- Travel & lodging$1,7394%
- Food & beverage$4,42610%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 147 | $43,123 |
| Neurocrine Biosciences, Inc. | 53 | $960 |
| Teva Pharmaceuticals USA, Inc. | 59 | $606 |
| Otsuka America Pharmaceutical, Inc. | 16 | $250 |
| Johnson & Johnson | 14 | $234 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $83 |
| Axsome Therapeutics, Inc. | 4 | $81 |
| Lundbeck LLC | 5 | $79 |
| Tris Pharma Inc | 3 | $49 |
| Alkermes, Inc. | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 3 | $44 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$35,223
How this compares
$45,827 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 95 | $133,476 |
| Risperdal ConstaRisperidone Microspheres | 36 | $50,819 |
| RexultiBrexpiprazole | 27 | $48,414 |
| Invega SustennaPaliperidone Palmitate | 14 | $34,197 |
| TrintellixVortioxetine Hydrobromide | 21 | $20,571 |
| Lamictal OdtLamotrigine | 16 | $12,233 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $8,200 |
| Ambien CrZolpidem Tartrate | 11 | $8,086 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 42 | $3,111 |
| Duloxetine Hcl | 81 | $2,517 |
| Quetiapine Fumarate | 216 | $2,382 |
| Clonazepam | 222 | $1,990 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 85 | $1,982 |
| Buspirone Hcl | 148 | $1,752 |
| Paliperidone ErPaliperidone | 14 | $1,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $43,123 | $133,47695 claims |
| Johnson & JohnsonRisperdal Consta, Invega Sustenna | $234 | $85,01750 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $250 | $48,41427 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $83 | $28,77142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Columbia
- Meera NarasimhanColumbia$57K
- Deborah LeveretteColumbia$11K
- Nioaka CampbellColumbia$11K
- Timothy MaloneColumbia$7K
- Kelly DionColumbia$7K
- Kevin KrebsColumbia$6K
- James RiddleColumbia$6K
- Lauren BarronColumbia$6K
- Robert SchnackenbergColumbia$6K
- Brittany AlbrightMount Pleasant$691K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.